Cardiff Oncology Q2 2022: $122M cash; preclinical ovarian data shows onvansertib + olaparib survival benefit

Cardiff Oncology, Inc.

2022-Q2 EPS reported -$0.50 revenue$165,000

Cash, equivalents, and short-term investments of ~$122M as of June 30, 2022; net cash used in Q2 2022 was $6.7M, up from $4.3M in Q2 2021.
R&D expenses rose to $7.45M from $4.12M YoY, driven by CMC and clinical pharmacology studies for onvansertib.
Preclinical ovarian cancer data at AACR: onvansertib + olaparib showed statistically significant survival benefit vs either agent alone in three PDX models.
Phase 2 mCRPC trial: 75% (15/20) of most dose-dense arm achieved stable disease or partial response at 12 weeks; response correlated with PTEN/MTOR mutations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.